Cuba’s pharmaceutical industry is working to expand its presence on the international market by commercializing new medicines.
Among the new medicines that might be exported during the 2008-2010 period is the pentavalent vaccine Heberpenta, which immunizes against diphtheria, tetanus, whooping cough, hepatitis B and the bacteria Haemophilus influenzae type B.
Heberpenta is produced by the company Heber Biotec S.A., which is the exclusive representative of the Genetic Engineering and Biotechnology Center and other Cuban scientific institutions.
The Cuban company will also export interferon gel to treat cervical-uterine cancer, and recombinant streptokinase (Heberkinasa), which destroys blood clots.
It also plans to commercialize a viscous solution containing Skin Growth Factor (Hebervis), which speeds up the regeneration of mucus and minimizes the secondary effects of radiotherapy treatments.